Close Menu
    Facebook X (Twitter) Instagram
    SciTechDaily
    • Biology
    • Chemistry
    • Earth
    • Health
    • Physics
    • Science
    • Space
    • Technology
    Facebook X (Twitter) Pinterest YouTube RSS
    SciTechDaily
    Home»Health»New Research Reveals That Long COVID Is Not a Single Condition
    Health

    New Research Reveals That Long COVID Is Not a Single Condition

    By University of Washington School of MedicineSeptember 11, 20231 Comment4 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email
    Coronavirus COVID 19 Virus Particles
    A recent nationwide study indicates that long COVID isn’t a singular condition and evolves over time. The research, involving almost 6,000 participants, highlighted varying symptom categories and emphasized the importance of tailored treatments based on the presentation of symptoms.

    The study revealed that symptoms evolve over time, with numerous patients experiencing headaches and fatigue.

    New data from a nationwide study recently published in the journal Open Forum of Infectious Diseases suggests that Long COVID is not a single condition, and should not be treated as such.

    This research examined the lasting symptoms of COVID-19 patients at both three and six months after diagnosis. Out of the 5,963 individuals who took part in the study, 4,504 had tested positive for COVID-19, while 1,459 tested negative. Many of the participants, 2,000 in all, came from King County through the University of Washington School of Medicine.

    The four major symptom categories for people who tested positive for COVID-19 included:

    • Minimal symptoms (72% of the cases)
    • Tiredness, headache, and muscle/joint aches (17% of cases)
    • Tiredness, headache, and muscle/joint aches with loss of taste and smell (5% of cases)
    • Symptoms across multiple systems (6% of cases)

    This study is clinically significant because it shows how the long-term symptoms from the virus changes its presentation over time, noted Kari Stephens, senior author and the Helen D. Cohen Endowed Professor and research section head in  the Department of Family Medicine and an adjunct professor in the Department of Biomedical Informatics and Medical Education at the University of Washington School of Medicine.

    Most long COVID studies have focused primarily on the individual symptoms without considering clusters or patterns of symptoms. Many did not have comparison groups and focused only on data captured by providers during clinic visits, rather than directly from patients, she said.

    “This study also gives providers information about how long-term outcomes for COVID may look and present in patients over time,” she said. “This study will help us understand how we need to treat long COVID over time, in very specific ways for each patient depending on how their symptoms present.”

    This study is unique in that people were able to report symptoms directly, regardless of whether or not they received medical care.

    “While it is becoming increasingly clear that long COVID is not a singular condition, having data showing several distinct, symptom-defined phenotypes is a strong step towards developing evidence-driven approaches to treat the millions of people who continue to experience lingering symptoms,” said Michael Gottlieb, vice chair of research for emergency medicine at Rush University Medical Center and lead author.

    Overall, the study will help determine funding and policy support for long COVID programs, Stephens added.

    “We don’t want to forget about long COVID as we all go back to “normal,”” Stephens said. “New long COVID cases are occurring every day.”

    Currently, the CDC estimates that 11% of those who contracted COVID-19 are now experiencing symptoms of long COVID.

    Reference: “Long COVID Clinical Phenotypes up to 6 Months After Infection Identified by Latent Class Analysis of Self-Reported Symptoms” by Michael Gottlieb, Erica S Spatz, Huihui Yu, Lauren E Wisk, Joann G Elmore, Nicole L Gentile, Mandy Hill, Ryan M Huebinger, Ahamed H Idris, Efrat R Kean, Katherine Koo, Shu-Xia Li, Samuel McDonald, Juan Carlos C Montoy, Graham Nichol, Kelli N O’Laughlin, Ian D Plumb, Kristin L Rising, Michelle Santangelo, Sharon Saydah, Ralph C Wang, Arjun Venkatesh, Kari A Stephens and Robert A Weinstein, 31 May 2023, Open Forum Infectious Diseases.
    DOI: 10.1093/ofid/ofad277

    The nearly 6,000 participants began self-reporting symptom data via detailed surveys beginning in December 2020 and were followed for up to 18 months. This part of the study concluded in September 2022.

    INSPIRE, or Innovative Support for Patients with SARS-CoV-2 Infections, is a federally funded collaboration of eight major academic medical centers, including UW Medicine, seeking to better understand the long-term effects of COVID. The patients were recruited from eight major health organizations and self-reported their symptoms in a standardized questionnaire. The INSPIRE group has been studying COVID since the first documented U.S. case was found just outside the Seattle area in January 2020. This is the sixth study released by the group.

    COVID-19 Long COVID University of Washington
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    New Biosensors Quickly Detect COVID-19 Coronavirus Proteins and Antibodies

    Gut Microbiome May Influence COVID-19 Severity and Immune Response – Also Implicated in “Long COVID”

    “You Do Not Want to Mess With This Virus” – Research Strongly Suggests COVID-19 Virus Enters the Brain

    COVID-19 Is Making Tinnitus Worse – Hearing Loss May Be “Long COVID” Symptom

    Ultrapotent COVID-19 Vaccine Designed via Computer: Innovative Nanoparticle Vaccine Spurs Extremely High Levels of Protective Antibodies

    Ultrapotent Antibody Mix Blocks COVID-19 Virus From Entering Cells – Protects Against the Pandemic Coronavirus

    Computer Designed Synthetic Antiviral Proteins Inhibit SARS-CoV-2 / COVID-19 in Human Cells

    COVID-19 Replicating RNA Vaccine Has Robust Response in Both Young and Old Animal Models

    Antibody Neutralizes SARS and COVID-19 Coronaviruses – On Accelerated Path Toward Clinical Trials

    1 Comment

    1. Patrick Marrs on September 13, 2023 3:26 am

      I still have diarrhea and internal vibrations or jitters

      Reply
    Leave A Reply Cancel Reply

    • Facebook
    • Twitter
    • Pinterest
    • YouTube

    Don't Miss a Discovery

    Subscribe for the Latest in Science & Tech!

    Trending News

    Could Perseverance’s Mars Samples Hold the Secret to Ancient Life?

    Giant Fossil Discovery in Namibia Challenges Long-Held Evolutionary Theories

    Is There Anybody Out There? The Hunt for Life in Cosmic Oceans

    Paleontological Surprise: New Research Indicates That T. rex Was Much Larger Than Previously Thought

    Photosynthesis-Free: Scientists Discover Remarkable Plant That Steals Nutrients To Survive

    A Waste of Money: New Study Reveals That CBD Is Ineffective for Pain Relief

    Two Mile Long X-Ray Laser Opens New Windows Into a Mysterious State of Matter

    650 Feet High: The Megatsunami That Rocked Greenland’s East Coast

    Follow SciTechDaily
    • Facebook
    • Twitter
    • YouTube
    • Pinterest
    • Newsletter
    • RSS
    SciTech News
    • Biology News
    • Chemistry News
    • Earth News
    • Health News
    • Physics News
    • Science News
    • Space News
    • Technology News
    Recent Posts
    • Mystery Solved: Scientists Discover Unique Evolutionary Branch of Snakes
    • Unlocking the Deep Past: New Study Maps the Dawn of Animal Life
    • Scientists Uncover How Cocaine Tricks the Brain Into Feeling Good – Breakthrough Could Lead to New Substance Abuse Treatments
    • Scientists Sound the Alarm: Record Ocean Heat Puts the Great Barrier Reef in Danger
    • New Study Unravels the Mystery of COVID’s Worst Pediatric Complication
    Copyright © 1998 - 2024 SciTechDaily. All Rights Reserved.
    • Latest News
    • Trending News
    • Privacy Policy
    • Terms of Use

    Type above and press Enter to search. Press Esc to cancel.